Soleno Therapeutics to Participate in Two Upcoming Investor Conferences

March 11, 2019

REDWOOD CITY, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a panel titled, “How Will Orphan & Ultra-Orphan Drugs Stand up Against Pricing Uncertainties?”, and provide a corporate update, at the 31st Annual ROTH Conference, taking place March 17-19, 2019, in Dana Point, CA. 

Dr. Bhatnagar will also present a corporate overview at the Oppenheimer & Co. 29th Annual Healthcare Conference, taking place March 19-20, 2019, in New York, NY.  The presentation will take place on Wednesday, March 20, at 10:55 AM ET, and will be webcast live at

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, is currently being evaluated in a Phase III clinical development program.

For more information, please visit

Brian Ritchie
LifeSci Advisors, LLC

Soleno Logo_2018.png

Source: Soleno Therapeutics